{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:13:19Z","timestamp":1791313999295,"version":"4.3.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,12,1]]},"DOI":"10.1093\/eurheartj\/ehi499","type":"journal-article","created":{"date-parts":[[2005,9,24]],"date-time":"2005-09-24T00:25:07Z","timestamp":1127521507000},"page":"2706-2713","source":"Crossref","is-referenced-by-count":146,"title":["Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure"],"prefix":"10.1093","volume":"26","author":[{"given":"Mattie J.","family":"Lenzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma J.M.","family":"Scholte op Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aggie H.M.M.","family":"Balk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Komajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Follath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Jimenez-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten L.","family":"Simoons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.F.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,9,23]]},"reference":[{"key":"key\n\t\t\t\t20171012011620_EHI499C1","doi-asserted-by":"crossref","unstructured":"Khand A, Gemmel I, Clark AL, Cleland JG. Is the prognosis of heart failure improving? J Am Coll Cardiol2000;36:2284\u20132286.","DOI":"10.1016\/S0735-1097(00)00995-5"},{"key":"key\n\t\t\t\t20171012011620_EHI499C2","doi-asserted-by":"crossref","unstructured":"Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol1993;22:6A\u201313A.","DOI":"10.1016\/0735-1097(93)90455-A"},{"key":"key\n\t\t\t\t20171012011620_EHI499C3","doi-asserted-by":"crossref","unstructured":"The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med1987;316:1429\u20131435.","DOI":"10.1056\/NEJM198706043162301"},{"key":"key\n\t\t\t\t20171012011620_EHI499C4","doi-asserted-by":"crossref","unstructured":"The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med1991;325:293\u2013302.","DOI":"10.1056\/NEJM199108013250501"},{"key":"key\n\t\t\t\t20171012011620_EHI499C5","doi-asserted-by":"crossref","unstructured":"Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med1992;327:669\u2013677.","DOI":"10.1056\/NEJM199209033271001"},{"key":"key\n\t\t\t\t20171012011620_EHI499C6","doi-asserted-by":"crossref","unstructured":"The MERIT-HF Study Group. Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet1999;353:2001\u20132007.","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"key\n\t\t\t\t20171012011620_EHI499C7","doi-asserted-by":"crossref","unstructured":"The CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet1999;353:9\u201313.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"key\n\t\t\t\t20171012011620_EHI499C8","doi-asserted-by":"crossref","unstructured":"Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med2001;344:1651\u20131658.","DOI":"10.1056\/NEJM200105313442201"},{"key":"key\n\t\t\t\t20171012011620_EHI499C9","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, The Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med1999;341:709\u2013717.","DOI":"10.1056\/NEJM199909023411001"},{"key":"key\n\t\t\t\t20171012011620_EHI499C10","doi-asserted-by":"crossref","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med2003;348:1309\u20131321.","DOI":"10.1056\/NEJMoa030207"},{"key":"key\n\t\t\t\t20171012011620_EHI499C11","unstructured":"The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J1995;16:741\u2013751."},{"key":"key\n\t\t\t\t20171012011620_EHI499C12","doi-asserted-by":"crossref","unstructured":"Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J1997;18:736\u2013753.","DOI":"10.1093\/oxfordjournals.eurheartj.a015339"},{"key":"key\n\t\t\t\t20171012011620_EHI499C13","doi-asserted-by":"crossref","unstructured":"Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J2001;22:1527\u20131560.","DOI":"10.1053\/euhj.2001.2783"},{"key":"key\n\t\t\t\t20171012011620_EHI499C14","doi-asserted-by":"crossref","unstructured":"Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J2005;26:1115\u20131140.","DOI":"10.1093\/eurheartj\/ehi204"},{"key":"key\n\t\t\t\t20171012011620_EHI499C15","doi-asserted-by":"crossref","unstructured":"Cohen-Solal A, Desnos M, Delahaye F, Emeriau JP, Hanania G. A national survey of heart failure in French hospitals. Eur Heart J2000;21:763\u2013769.","DOI":"10.1053\/euhj.1999.1762"},{"key":"key\n\t\t\t\t20171012011620_EHI499C16","doi-asserted-by":"crossref","unstructured":"Cowie MR, Wood DA, Coats AJS, Thompson SG, Suresh V, Poole-Wilson PA, Sutton GC. Survival of patients with a new diagnosis of heart failure: a population based study. Heart2000;83:505\u2013510.","DOI":"10.1136\/heart.83.5.505"},{"key":"key\n\t\t\t\t20171012011620_EHI499C17","doi-asserted-by":"crossref","unstructured":"MacIntyre K, Capewell S, Stewart S, Chalmers JWT, Boyd J, Finlayson A, Redpath A, Pell JP, McMurray JJV. Evidence of improving prognosis in heart failure: trends in case fatality in 66\u2005547 patients hospitalized between 1986 and 1995. Circulation2000;102:1126\u20131131.","DOI":"10.1161\/01.CIR.102.10.1126"},{"key":"key\n\t\t\t\t20171012011620_EHI499C18","doi-asserted-by":"crossref","unstructured":"Mehta PA, McDonagh S, Poole-Wilson PA, Grocott-Mason R, Dubrey SW. Heart failure in a district general hospital: are target doses of beta-blockers realistic? Quart J Med2004;97:133\u2013139.","DOI":"10.1093\/qjmed\/hch023"},{"key":"key\n\t\t\t\t20171012011620_EHI499C19","doi-asserted-by":"crossref","unstructured":"Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J. The EuroHeart Failure survey programme\u2014a survey on the quality of care among patients with heart failure in Europe: Part 1: patient characteristics and diagnosis. Eur Heart J2003;24:442\u2013463.","DOI":"10.1016\/S0195-668X(02)00823-0"},{"key":"key\n\t\t\t\t20171012011620_EHI499C20","doi-asserted-by":"crossref","unstructured":"Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH. The EuroHeart Failure Survey programme\u2014a survey on the quality of care among patients with heart failure in Europe: Part 2: treatment. Eur Heart J2003;24:464\u2013474.","DOI":"10.1016\/S0195-668X(02)00700-5"},{"key":"key\n\t\t\t\t20171012011620_EHI499C21","unstructured":"Cowie MR. Best practice: evidence from the clinical trials. Heart2002;88:ii2\u2013ii4."},{"key":"key\n\t\t\t\t20171012011620_EHI499C22","doi-asserted-by":"crossref","unstructured":"Lloyd-Williams F, Mair F, Shiels C, Hanratty B, Goldstein P, Beaton S, Capewell S, Lye M, Mcdonald R, Roberts C, Connelly D. Why are patients in clinical trials of heart failure not like those we see in everyday practice? J Clin Epidemiol2003;56:1157\u20131162.","DOI":"10.1016\/S0895-4356(03)00205-1"},{"key":"key\n\t\t\t\t20171012011620_EHI499C23","doi-asserted-by":"crossref","unstructured":"Sharpe N. Clinical trials and the real world: selection bias and generalisability of trial results. Cardiovasc Drugs Ther2002;16:75\u201377.","DOI":"10.1023\/A:1015327801114"},{"key":"key\n\t\t\t\t20171012011620_EHI499C24","doi-asserted-by":"crossref","unstructured":"Konstam MA. Progress in heart failure management? Lessons from the real world. Circulation2000;102:1076\u20131078.","DOI":"10.1161\/01.CIR.102.10.1076"},{"key":"key\n\t\t\t\t20171012011620_EHI499C25","doi-asserted-by":"crossref","unstructured":"Knottnerus JA, Dinant GJ. Medicine based evidence, a prerequisite for evidence-based medicine. BMJ1997;315:1109\u20131110.","DOI":"10.1136\/bmj.315.7116.1109"},{"key":"key\n\t\t\t\t20171012011620_EHI499C26","doi-asserted-by":"crossref","unstructured":"Masoudi FA, Havranek EP, Wolfe P, Gross CP, Rathore SS, Steiner JF, Ordin DL, Krumholz HM. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J2003;146:250\u2013257.","DOI":"10.1016\/S0002-8703(03)00189-3"},{"key":"key\n\t\t\t\t20171012011620_EHI499C27","unstructured":"Hickling SRINJA. The barriers to effective management of heart failure in general practice. Br J Gen Pract2001;51:615\u2013618."},{"key":"key\n\t\t\t\t20171012011620_EHI499C28","doi-asserted-by":"crossref","unstructured":"Cleland JGF, Swedberg K, Cohen-Solal A, Cosin-Aguilar J, Dietz R, Follath F, Gavazzi A, Hobbs R, Korewicki J, Madeira HC. The Euro Heart Failure Survey of The EUROHEART Survey Programme: A survey on the quality of care among patients with heart failure in Europe. Eur J Heart Fail2000;2:123\u2013132.","DOI":"10.1016\/S1388-9842(00)00081-7"},{"key":"key\n\t\t\t\t20171012011620_EHI499C29","doi-asserted-by":"crossref","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362:777\u2013781.","DOI":"10.1016\/S0140-6736(03)14285-7"},{"key":"key\n\t\t\t\t20171012011620_EHI499C30","doi-asserted-by":"crossref","unstructured":"Squire IB. Angiotensin converting enzyme inhibition in heart failure: clinical trials and clinical practice. Cardiovasc Drugs Ther2002;16:67\u201374.","DOI":"10.1023\/A:1015375717044"},{"key":"key\n\t\t\t\t20171012011620_EHI499C31","doi-asserted-by":"crossref","unstructured":"Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA, on behalf of the SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J2005;26:215\u2013225.","DOI":"10.1093\/eurheartj\/ehi115"},{"key":"key\n\t\t\t\t20171012011620_EHI499C32","doi-asserted-by":"crossref","unstructured":"Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction >or=40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol1997;80:207\u2013209.","DOI":"10.1016\/S0002-9149(97)00320-2"},{"key":"key\n\t\t\t\t20171012011620_EHI499C33","doi-asserted-by":"crossref","unstructured":"Lenzen MJ, Scholte op Reimer WJM, Boersma E, Vantrimpont PJMJ, Follath F, Swedberg K, Cleland J, Komajda M. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J2004;25:1214\u20131220.","DOI":"10.1016\/j.ehj.2004.06.006"},{"key":"key\n\t\t\t\t20171012011620_EHI499C34","doi-asserted-by":"crossref","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med2004;351:543\u2013551.","DOI":"10.1056\/NEJMoa040135"},{"key":"key\n\t\t\t\t20171012011620_EHI499C35","doi-asserted-by":"crossref","unstructured":"Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ2003;327:1141\u20131142.","DOI":"10.1136\/bmj.327.7424.1141"},{"key":"key\n\t\t\t\t20171012011620_EHI499C36","doi-asserted-by":"crossref","unstructured":"Cleland JGF, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F, Freemantle N, Gavazzi A, van Gilst WH, Hobbs FDR. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet2002;360:1631\u20131639.","DOI":"10.1016\/S0140-6736(02)11601-1"},{"key":"key\n\t\t\t\t20171012011620_EHI499C37","doi-asserted-by":"crossref","unstructured":"Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA1999;282:1458\u20131465.","DOI":"10.1001\/jama.282.15.1458"},{"key":"key\n\t\t\t\t20171012011620_EHI499C38","doi-asserted-by":"crossref","unstructured":"Pfeffer MA, Stevenson LW. {beta}-Adrenergic blockers and survival in heart failure. N Engl J Med1996;334:1396\u20131397.","DOI":"10.1056\/NEJM199605233342109"},{"key":"key\n\t\t\t\t20171012011620_EHI499C39","doi-asserted-by":"crossref","unstructured":"Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation1999;100:2312\u20132318.","DOI":"10.1161\/01.CIR.100.23.2312"},{"key":"key\n\t\t\t\t20171012011620_EHI499C40","doi-asserted-by":"crossref","unstructured":"The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J1998;19:481\u2013489.","DOI":"10.1053\/euhj.1997.0839"},{"key":"key\n\t\t\t\t20171012011620_EHI499C41","doi-asserted-by":"crossref","unstructured":"Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation1999;100:2312\u20132318.","DOI":"10.1161\/01.CIR.100.23.2312"},{"key":"key\n\t\t\t\t20171012011620_EHI499C42","doi-asserted-by":"crossref","unstructured":"Wikstrand J, Hjalmarson Ak, Waagstein F, Fagerberg Bj, Goldstein S, Kjekshus J, Wedel H. Dose of metoprolol CR\/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR\/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol2002;40:491\u2013498.","DOI":"10.1016\/S0735-1097(02)01970-8"},{"key":"key\n\t\t\t\t20171012011620_EHI499C43","doi-asserted-by":"crossref","unstructured":"Simon T, Mary-Krause M, Funck-Brentano C, Lechat P, Jaillon P, on behalf of CIBIS II investigators. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J2003;24:552\u2013559.","DOI":"10.1016\/S0195-668X(02)00743-1"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/26\/24\/2706\/9624788\/ehi499.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T21:50:22Z","timestamp":1586469022000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/eurheartj\/article\/26\/24\/2706\/2888050\/Underutilization-of-evidencebased-drug-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,23]]},"references-count":43,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2005,9,23]]},"published-print":{"date-parts":[[2005,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehi499","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,12]]},"published":{"date-parts":[[2005,9,23]]}}}